Clinical Trial Update: A Phase 3 Adaptive Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Participants With Pulmonary Hypertension (PH) Due to Chronic Obstructive Pulmonary Disease (COPD) [Phase 3]

View source ↗

Summary

A Phase 3 adaptive trial evaluating inhaled treprostinil for pulmonary hypertension due to COPD was terminated; results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Pulmonary Hypertension

Drugs mentioned

• Treprostinil (treprostinil)

Snippet

Sponsor: United Therapeutics | Conditions: Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease | Phase 3 | Status: TERMINATED | Results posted: 2023-11-24